In short
This article discusses an ongoing clinical trial investigating the use of human fetal neural precursor cells (hfNPCs), a type of human neuronal progenitor/stem cells, as a potential treatment for progressive multiple sclerosis (PMS). The study aims to evaluate the safety and efficacy of intrathecal administration of these cells compared to a sham procedure in patients with PMS. This phase 2 trial represents an important step in exploring innovative cellular therapies for this challenging neurological condition.
At a glance
- Study Type
- Phase 2, randomized, patient and assessor blind, multicentre study
- Condition
- Progressive Multiple Sclerosis (PMS)
- Intervention
- Human fetal neural precursor cells (hfNPCs) transplantation
- Dosage
- Two intrathecal administrations of 200 x 10^6±10% cells, six months apart
- Control
- Sham procedure
- Primary Outcome
- Change in whole brain volume (MRI) over 96 weeks
- Key Secondary Outcomes
- Safety, brain grey/white matter volume changes, disability progression, cognitive function
- Eligibility
- Adults 18-65 with PMS, EDSS 3.0-8.0, failed/intolerant to approved therapies
- Follow-up Duration
- 96 weeks post-treatment
What are Human Fetal Neural Precursor Cells (hfNPCs)?
Human Fetal Neural Precursor Cells (hfNPCs), also known as human neuronal progenitor/stem cells, are a type of cell therapy being investigated for the treatment of progressive multiple sclerosis (PMS). These cells have the potential to develop into various types of cells found in the nervous system, which makes them a promising candidate for treating neurological conditions like multiple sclerosis.
Treatment for Progressive Multiple Sclerosis
Progressive Multiple Sclerosis (PMS) is a form of multiple sclerosis characterized by a steady worsening of neurological function. The use of hfNPCs is being studied as a potential treatment for PMS patients who have not responded well to other approved therapies or are ineligible for them.
How are hfNPCs Administered?
In the clinical trial, hfNPCs are administered through intrathecal (IT) injection. This means the cells are injected directly into the fluid surrounding the brain and spinal cord. The treatment involves two separate administrations, each consisting of approximately 200 million cells, given six months apart.
The STEMS2 Clinical Trial
The STEMS2 trial is a Phase 2 clinical study investigating the use of hfNPCs for treating progressive multiple sclerosis. Key features of the trial include:
- It is a randomized, patient and assessor blind, multicentre study.
- Participants are randomly assigned to receive either hfNPC transplantation or a sham procedure.
- The study includes a 96-week follow-up period to assess the long-term effects of the treatment.
Who is Eligible for the Trial?
The trial has specific inclusion and exclusion criteria. Some key eligibility factors include:
- Participants must be between 18 and 65 years old.
- Diagnosed with Progressive Multiple Sclerosis.
- Have an Expanded Disability Status Scale (EDSS) score between 3.0 and 8.0. This scale measures the degree of disability in MS patients.
- Have failed, been intolerant to, or ineligible for approved therapies.
There are also several exclusion criteria, such as certain medical conditions or recent use of specific medications, that may prevent participation.
Trial Objectives and Endpoints
The main goal of the STEMS2 trial is to evaluate how well hfNPCs work in treating PMS compared to a sham procedure. The study will measure several outcomes, including:
- Changes in brain volume over 96 weeks.
- The proportion of patients without disease progression.
- Changes in cognitive function.
Safety Considerations
As with any clinical trial, safety is a primary concern. The study will closely monitor participants for any adverse events related to the treatment. Additionally, participants will receive tacrolimus, an immunosuppressive medication, for 24 weeks after each hfNPC administration to help prevent rejection of the transplanted cells.
It's important to note that while this treatment shows promise, it is still experimental and its long-term effects and efficacy are not yet fully known. Patients considering participation in this or any clinical trial should discuss the potential risks and benefits thoroughly with their healthcare providers.